Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Industry and advocates urge regulation, not bans; scientists and public‑health officials dispute evidence
Summary
Industry and consumer groups pushed the Senate committee to limit policy to concentrated synthetic 7OH while preserving access to natural kratom; public‑health witnesses and some scientists warned that flawed studies complicate interpretation and enforcement challenges remain.
The Senate Health informational hearing also foregrounded a sharp policy debate: industry and consumer advocates urged a regulatory framework that preserves access to natural whole‑leaf kratom while banning or restricting concentrated synthetic 7‑hydroxymitragynine (7OH); public‑health experts and some scientists said the evidence and enforcement realities complicate a straightforward distinction.
Matthew Lowe, executive director of the Global Kratom Coalition, told the committee that natural kratom leaf has decades of use and that concentrated or synthetically produced 7OH products are a distinct exposure class that…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
